Sunday 18 October 2026
Export XAIR’s income statement to Excel — free account
Beyond Air, Inc.
XAIR Healthcare Medical Devices
Beyond Air, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $7.7 million, up 107.3% from fiscal 2025. In the quarter to June 2026, revenue was flat, EPS grew 64.1%, free cash flow fell 9.10% and total debt rose 127.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.16
0.05
−2.26%
Follow XAIR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 70.20 | 41.00 | 1,380.00 | 1,488.00 | 1,848.00 | 1,914.00 | 468.00 | 118.40 | 13.46 | 2.05 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | 600.00 | 2,196.00 | 2,499.60 | 5,000.00 | 6,564.00 | 4,704.00 | 3,096.00 | 868.00 | 208.00 | 53.20 | |||||
| People | |||||||||||||||
| People | Employees | 12 | — | 18 | 23 | 45 | 70 | 98 | 107 | 61 | 54 | ||||
| Revenue/emp, $m | 0.00 | — | 0.43 | 0.06 | 0.02 | 0.00 | 0.00 | 0.01 | 0.06 | 0.14 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 8 | 1 | 1 | — | — | 1 | 4 | 8 | ||||
| Gross margin, % | 0.00 | — | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | (112.77) | (44.89) | 3.28 | |||||
| EBT | (18) | — | (7) | (20) | (23) | (44) | (59) | (64) | (48) | (34) | |||||
| EBT margin, % | 0.00 | — | (85.30) | (1,445.71) | (2,620.27) | 0.00 | 0.00 | (5,547.45) | (1,308.48) | (447.12) | |||||
| Net income | (18) | — | (7) | (20) | (23) | (44) | (59) | (64) | (48) | (34) | |||||
| Depreciation | 0 | — | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 4 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | — | 364.34 | 48.27 | 19.40 | 0.00 | 0.00 | 13.98 | 21.88 | 18.50 | ||||
| Earnings | (1,202.53) | — | (308.67) | (712.00) | (508.00) | (672.00) | (744.00) | (728.00) | (276.00) | (80.20) | |||||
| Cash flow | (474.60) | — | 63.26 | (529.52) | (436.42) | (360.34) | (440.71) | (675.68) | (225.74) | (43.71) | |||||
| Capex | (16.27) | — | (2.67) | (1.51) | (19.78) | (21.50) | (51.76) | (69.30) | (34.75) | (2.47) | |||||
| Free cash flow | (490.87) | — | 60.59 | (531.03) | (456.20) | (381.84) | (492.47) | (744.98) | (260.49) | (46.18) | |||||
| Book value | (558.60) | — | 189.85 | 628.21 | 676.98 | 1,218.21 | 561.12 | 327.94 | 84.71 | 14.96 | |||||
| Shares, m | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 0.00 | 84.71 | 113.40 | — | — | 45.21 | 4.99 | 0.75 | |||||
| P/B | — | — | 10.04 | 6.51 | 3.25 | — | — | 1.93 | 1.29 | 0.92 | |||||
| EV/Sales | — | — | 0.00 | 69.75 | 78.76 | — | — | 28.66 | 5.71 | 1.37 | |||||
| EV/FCF | — | — | 28.60 | (6.34) | (3.35) | — | — | (0.54) | (0.48) | (0.55) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (7) | — | 1 | (15) | (20) | (23) | (33) | (56) | (38) | (18) | ||||
| Capex | 0 | — | 0 | 0 | (1) | (1) | (4) | (6) | (6) | (1) | |||||
| Free cash flow | (7) | — | 1 | (15) | (21) | (25) | (37) | (62) | (44) | (19) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 1 | — | 3 | 22 | 33 | 82 | 40 | 32 | 11 | 18 | ||||
| Total debt | 0 | — | 0 | 5 | 5 | 1 | 1 | 16 | 10 | 22 | |||||
| Net debt | (2) | — | (8) | (21) | (30) | (89) | (53) | (19) | 3 | 5 | |||||
| Shareholders’ equity | (8) | — | 4 | 18 | 30 | 78 | 42 | 27 | 14 | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (824.30) | — | (112.91) | (111.03) | (67.32) | (61.80) | (66.47) | (95.84) | (107.16) | (101.61) | ||||
| ROIC | 0.00 | — | 0.00 | 0.00 | (6,170.28) | 0.00 | 0.00 | (491.69) | (163.75) | (165.22) | |||||
| ROE | 215.32 | — | 301.12 | (185.06) | (94.22) | (79.46) | (92.84) | (174.07) | (224.55) | (323.58) | |||||
Negative figures in brackets.
Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 28 Sep 2026
Charts ten years each
Beyond Air, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADGM Adagio Medical Holdings, Inc. | $2.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.8M | 0.0× | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| NXL Nexalin Technology, Inc. | $2.6M | — (loss-making) | — (loss-making) | −82.72% (below 0%: shrinking) | n/m | −97.23% (below 0%: shrinking) | 72.95% | (18,420.49%) | Compare |
| BIOLQ Biolase, Inc. | $2.3M | — (loss-making) | — (loss-making) | −0.65% (below 0%: shrinking) | n/m | −60.22% (below 0%: shrinking) | 40.39% | (6.41%) | Compare |
| XAIR Beyond Air, Inc. | $2.2M | — (loss-making) | — (loss-making) | +0.45% (above 0%: growing) | n/m | −9.10% (below 0%: shrinking) | 12.73% | (373.98%) | |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VJET Flyte Aviation, Inc. | $2.1M | — (loss-making) | — (loss-making) | +380.66% (above 0%: growing) | n/m | −26.70% (below 0%: shrinking) | 9.62% | (388.13%) | Compare |
| NUWE Nuwellis, Inc. | $2.0M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| AFIB Acutus Medical, Inc. | $1.7M | — (loss-making) | — (loss-making) | +204.18% (above 0%: growing) | n/m | +76.40% (above 0%: growing) | 14.20% | (3.81%) | Compare |
| Median of peers | $2.2M | — | — | +14.14% | — | −19.78% | 24.63% | (32.84%) |
Beyond Air, Inc. (XAIR) key facts
- Strength: Beyond Air, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $7.7 million, up 107.3% from fiscal 2025.
- Beyond Air, Inc. (XAIR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, XAIR traded at $2.16, a market capitalization of $2.2 million.
- Return on equity was −323.6% and debt-to-equity 7.89.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −14.40 (distress zone) for fiscal 2026.
Beyond Air, Inc. (XAIR) Latest News
No news at this impact. Lower the threshold for more.